KR20220122652A - TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 - Google Patents
TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 Download PDFInfo
- Publication number
- KR20220122652A KR20220122652A KR1020227022860A KR20227022860A KR20220122652A KR 20220122652 A KR20220122652 A KR 20220122652A KR 1020227022860 A KR1020227022860 A KR 1020227022860A KR 20227022860 A KR20227022860 A KR 20227022860A KR 20220122652 A KR20220122652 A KR 20220122652A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acid
- seq
- acid sequence
- ser
- isvd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944619P | 2019-12-06 | 2019-12-06 | |
| US62/944,619 | 2019-12-06 | ||
| EP20305056 | 2020-01-23 | ||
| EP20305056.2 | 2020-01-23 | ||
| EP20000090.9 | 2020-02-28 | ||
| EP20000090 | 2020-02-28 | ||
| EP20305216 | 2020-03-02 | ||
| EP20305216.2 | 2020-03-02 | ||
| PCT/EP2020/084430 WO2021110816A1 (en) | 2019-12-06 | 2020-12-03 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220122652A true KR20220122652A (ko) | 2022-09-02 |
Family
ID=73642903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227022860A Withdrawn KR20220122652A (ko) | 2019-12-06 | 2020-12-03 | TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
Country Status (14)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| LT3248986T (lt) | 2014-05-16 | 2022-03-25 | Ablynx Nv | Imunoglobulino kintami domenai |
| WO2020144164A1 (en) | 2019-01-07 | 2020-07-16 | Bactolife Aps | Pathogen binding proteins |
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| EP4069733A1 (en) | 2019-12-06 | 2022-10-12 | Ablynx N.V. | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23 |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| IL322519A (en) | 2023-02-17 | 2025-10-01 | Ablynx Nv | Polypeptides that bind to the neonatal fc receptor |
| EP4438614A1 (en) | 2023-03-31 | 2024-10-02 | Sanofi | Methods for purifying heteromultimeric antibodies |
| US20250236673A1 (en) * | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
| CN118687298A (zh) | 2024-07-29 | 2024-09-24 | 上海原能细胞生物低温设备有限公司 | 一种立式低温存储冰箱 |
| CN119371530B (zh) * | 2024-11-06 | 2025-05-20 | 北京科道博济生物科技有限公司 | 一种靶向il-23a的纳米抗体及其应用 |
| CN121824755A (zh) * | 2026-01-16 | 2026-04-10 | 天津科道博济生物科技有限公司 | 一种靶向il-23a的纳米检测抗体及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| CA2706425A1 (en) * | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| LT3466972T (lt) | 2011-06-23 | 2026-06-25 | Ablynx Nv | Serumo albuminą surišantys baltymai |
| LT3248986T (lt) | 2014-05-16 | 2022-03-25 | Ablynx Nv | Imunoglobulino kintami domenai |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| EP3365371B1 (en) * | 2015-10-22 | 2025-10-08 | Ablynx NV | Gitr agonists |
| NO2768984T3 (cg-RX-API-DMAC7.html) | 2015-11-12 | 2018-06-09 | ||
| HUE057241T2 (hu) | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| EP3414268A1 (en) * | 2016-02-12 | 2018-12-19 | Ablynx NV | Method for the production of immunoglobulin single variable domains |
| WO2018104444A1 (en) | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3571224B1 (en) | 2017-01-17 | 2024-08-07 | Ablynx NV | Improved serum albumin binders |
| EP4442709A3 (en) | 2017-01-17 | 2024-12-25 | Ablynx NV | Improved serum albumin binders |
| AR112341A1 (es) | 2017-08-02 | 2019-10-16 | Lilly Co Eli | ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG |
| EP4069733A1 (en) | 2019-12-06 | 2022-10-12 | Ablynx N.V. | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23 |
-
2020
- 2020-12-03 EP EP20816198.4A patent/EP4069733A1/en active Pending
- 2020-12-03 AU AU2020396204A patent/AU2020396204A1/en not_active Abandoned
- 2020-12-03 MX MX2022006880A patent/MX2022006880A/es unknown
- 2020-12-03 WO PCT/EP2020/084430 patent/WO2021110816A1/en not_active Ceased
- 2020-12-03 CN CN202080083442.0A patent/CN114981300B/zh active Active
- 2020-12-03 CA CA3163877A patent/CA3163877A1/en active Pending
- 2020-12-03 KR KR1020227022860A patent/KR20220122652A/ko not_active Withdrawn
- 2020-12-03 BR BR112022009799A patent/BR112022009799A2/pt not_active Application Discontinuation
- 2020-12-03 JP JP2022533410A patent/JP7657797B2/ja active Active
- 2020-12-03 IL IL293561A patent/IL293561A/en unknown
- 2020-12-03 PH PH1/2022/551214A patent/PH12022551214A1/en unknown
- 2020-12-04 TW TW109142821A patent/TW202134269A/zh unknown
- 2020-12-04 US US17/111,689 patent/US20210188963A1/en not_active Abandoned
-
2021
- 2021-10-15 US US17/502,332 patent/US11332525B2/en active Active
-
2022
- 2022-04-25 US US17/727,876 patent/US12528860B2/en active Active
- 2022-04-25 US US17/727,868 patent/US20220372128A1/en active Pending
- 2022-07-01 CO CONC2022/0009239A patent/CO2022009239A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11332525B2 (en) | 2022-05-17 |
| CN114981300B (zh) | 2025-10-31 |
| US12528860B2 (en) | 2026-01-20 |
| EP4069733A1 (en) | 2022-10-12 |
| US20220064281A1 (en) | 2022-03-03 |
| TW202134269A (zh) | 2021-09-16 |
| PH12022551214A1 (en) | 2023-10-09 |
| AU2020396204A1 (en) | 2022-07-28 |
| BR112022009799A2 (pt) | 2022-08-16 |
| US20220363747A1 (en) | 2022-11-17 |
| CN114981300A (zh) | 2022-08-30 |
| WO2021110816A1 (en) | 2021-06-10 |
| JP7657797B2 (ja) | 2025-04-07 |
| US20210188963A1 (en) | 2021-06-24 |
| CA3163877A1 (en) | 2021-06-10 |
| IL293561A (en) | 2022-08-01 |
| US20220372128A1 (en) | 2022-11-24 |
| JP2023505492A (ja) | 2023-02-09 |
| CO2022009239A2 (es) | 2022-07-29 |
| MX2022006880A (es) | 2022-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12528860B2 (en) | Polypeptides comprising immunoglobulin single variable domains targeting TNFα and IL-23 | |
| TWI861302B (zh) | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 | |
| US11208476B2 (en) | Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP | |
| US20210188986A1 (en) | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l | |
| US12509522B2 (en) | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40L | |
| US11897951B2 (en) | Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α | |
| RU2846433C1 (ru) | Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на tnfa и ox40l | |
| CN116615453A (zh) | 包含靶向IL-6和TNF-α的免疫球蛋白单可变结构域的多肽 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PC1203 | Withdrawal of no request for examination |
St.27 status event code: N-1-6-B10-B12-nap-PC1203 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 St.27 status event code: A-3-3-R10-R13-asn-PN2301 |